Document is current

Any future updates will be listed below

Retention of the second-line biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis failing one tumor necrosis factor alpha inhibitor: data from the BioRx.si registry

Crossref DOI link: https://doi.org/10.1007/s10067-015-3066-z

Published Online: 2015-09-07

Published Print: 2015-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark